Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIDEA.L Regulatory News (IDEA)

  • There is currently no data for IDEA

Pre-Close Trading Update

14 May 2015 07:00

RNS Number : 1134N
Ideagen PLC
14 May 2015
 

 

 

Ideagen plc

("Ideagen" or the "Group'')

 

Pre-Close Trading Update

 

Ideagen PLC (AIM: IDEA), a leading supplier of Information Management software to highly regulated industries, announces a trading update for the year ended 30 April 2015.

 

Trading for the year to 30 April 2015 was robust and in line with expectations with both continued organic growth and contributions from EIBS and Gael. The results will therefore show the Group's sixth consecutive year of revenue and EBITDA* growth, with revenue expected to be up 59 per cent. to approximately £14.3 million and adjusted EBITDA expected to be up by 42 per cent. to approximately £4 million. This will lead to a significant increase in adjusted EPS** which continues to be an important financial metric for the Group and has averaged growth of 24 per cent. per annum since 2012.

 

Cash at 30 April was £5.25m and with no debt our strong balance sheet provides the Group with the capacity to pursue further strategic opportunities in the current financial year.

 

*Earnings before interest, tax, depreciation, amortisation, share based payments, acquisition costs and exceptional items.

** Adjusted fully diluted earnings per share,

 

Performance and Integration of Gael

 

The acquisition of Gael has transformed the Group and has made a strong and positive contribution both financially and in terms of product capability. Integration is well underway and a number of existing Ideagen customers have upgraded their existing installations to take advantage of the enhanced proposition that the Group can now offer. Having successfully executed our immediate objectives we can now accelerate the integration of Gael into the Group. To enable this Ashley Marron, Chief Executive of Gael has been appointed Group Chief Operating Officer with responsibility for all of Ideagen's Product Strategy and Development and Customer Services.

 

Outlook

 

The Group has significant contracted work in progress, a growing recurring revenue base and a strong pipeline of new business. We have experienced robust growth within our Commercial Markets such as Manufacturing, Life Sciences, Aviation and Banking which, we expect to continue. We are also seeing renewed momentum within a number of sales opportunities at NHS Hospital Trusts, which had slowed prior to the election. The Board is therefore confident that the Group will continue to meet its growth objectives for this financial year and beyond.

 

David Hornsby, Chief Executive, commented: "The Group has once again met market expectations, demonstrating the strength of our business model and products and the talent and dedication of our employees. I am delighted with the contribution from our newly acquired businesses, Gael and EIBS, and look forward to an exciting year ahead

 

 

 

Enquiries:

Ideagen Plc

Tel: 01629 699100

David Hornsby (Chief Executive)

 

Graeme Spenceley (Finance Director)

 

 

 

finnCap (Nominated Adviser and Broker)

Tel: 020 7220 0500

Stuart Andrews, James Thompson (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

 

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQXLFFEEFBBBE
Date   Source Headline
12th Nov 20207:00 amRNSPre-Close Trading Update and Board Changes
5th Nov 202010:46 amRNSPDMR Shareholding and Exercise of Options
4th Nov 20202:30 pmRNSHolding(s) in Company
29th Oct 202011:28 amRNSHolding(s) in Company
28th Oct 20203:59 pmRNSResult of AGM
21st Oct 20202:59 pmRNSHolding(s) in Company
16th Oct 202012:44 pmRNSExercise of share options and Total Voting Rights
14th Oct 20207:00 amRNSIssue of Equity and Total Voting Rights
5th Oct 20202:19 pmRNSNotice of AGM
2nd Oct 20201:52 pmRNSHolding(s) in Company
1st Oct 20208:28 amRNSPDMR Dealing and Exercise of Options
29th Sep 20205:51 pmRNSIssue of New Shares
22nd Sep 20207:00 amRNSFinal Results
15th Sep 20203:10 pmRNSHolding(s) in Company
24th Aug 20202:36 pmRNSHolding(s) in Company
19th Aug 20203:55 pmRNSIssue of New Shares
10th Aug 20207:00 amRNSTrading Update and Acquisition of Qualsys Ltd
14th Jul 20208:44 amRNSExercise of Options and TVR
1st Jul 20207:00 amRNSBoard Changes
24th Jun 20204:41 pmRNSSecond Price Monitoring Extn
24th Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 20207:00 amRNSExercise of Options and Total Voting Rights
16th Jun 20207:00 amRNSExercise of Options and TVR
26th May 20208:30 amRNSExercise of Options and TVR
22nd May 20207:00 amRNSPartnership with the World Health Organisation
21st May 20201:06 pmRNSHolding(s) in Company
19th May 20207:00 amRNSPre-Close Trading Update
28th Apr 20202:26 pmRNSExercise of Options and TVR
22nd Apr 20207:00 amRNSIssue of New Shares, Director Dealings and TVR
9th Apr 20207:00 amRNSExercise of Options and TVR
7th Apr 20207:00 amRNSCOVID-19 Trading Update
30th Mar 20207:00 amRNSIssue of new shares under SIP and TVR
6th Mar 20207:00 amRNSAcquisition of Workrite Ltd
25th Feb 202011:09 amRNSIssue of Equity
27th Jan 20204:56 pmRNSExercise of Options and TVR
22nd Jan 20207:00 amRNSInterim Results
20th Jan 20205:10 pmRNSIssue of Equity under Share Incentive Plan
7th Jan 20207:00 amRNSBoard Change
17th Dec 20194:08 pmRNSIssue of Equity
13th Dec 20194:38 pmRNSDirector/PDMR Shareholding
3rd Dec 20192:44 pmRNSHolding(s) in Company
2nd Dec 201911:29 amRNSPDMR Dealing and Total Voting Rights
29th Nov 20199:57 amRNSHolding(s) in Company
21st Nov 20194:06 pmRNSHolding(s) in Company
20th Nov 201911:58 amRNSDirector/PDMR Dealings and Total Voting Rights
18th Nov 20192:00 pmRNSIssue of Shares under Share Incentive Plan
13th Nov 20197:00 amRNSTrading Update
30th Oct 20193:48 pmRNSResult of AGM
24th Oct 20197:00 amRNSBoard Change
23rd Oct 201911:45 amRNSShare Incentive Plan and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.